Fangzhou Inc. Teams Up with Innovent Biologics
Fangzhou Inc. (06086.HK), a frontrunner in AI-driven Internet healthcare solutions, has announced an exciting new strategic partnership with Innovent Biologics. The aim of this collaboration is to merge digital health services with cutting-edge innovative therapies, particularly focusing on metabolic diseases and weight management. The signing ceremony was graced by notable leaders including Dr. Xie Fangmin, the founder, chairman, and CEO of Fangzhou, and Tan Zaiqiang, Vice President of Retail at Innovent Biologics.
Revolutionizing Weight Management
This alliance represents a significant step forward in providing comprehensive healthcare solutions for individuals dealing with weight issues. Fangzhou's AI-enabled “H2H” digital healthcare ecosystem will work hand in hand with Innovent’s innovative pipeline aimed at treating diabetes and obesity. As China’s weight management market is on the rise, projections by JPMorgan suggest it could reach a staggering US$14.9 billion by 2030, highlighting the urgent need for such partnerships.
A National Public Health Priority
Recognizing the growing concern around obesity, China has designated weight management as a public health priority. In a progressive initiative, the National Health Commission, along with 15 other departments, launched a campaign dedicated to weight management. This initiative was further supported by the National Patriotic Health Campaign Committee, which aims to integrate healthy weight initiatives into the broader “Healthy China” framework.
Innovative Healthcare Solutions
Dr. Xie Fangmin expressed enthusiasm for this partnership, stating, "We are excited to partner with Innovent Biologics. Together, we will work to establish a new paradigm that integrates breakthrough medicines with digital health for better patient outcomes." This collaboration will focus primarily on obesity and diabetes, leveraging Fangzhou’s sophisticated “XS Core” AI large language model. This powerful model facilitates five key products aimed at enhancing patient engagement: the AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search.
Enhancing Patient Support
By integrating these advanced tools, Fangzhou aims to provide personalized and around-the-clock digital care, significantly enhancing patient education and engagement. The innovative weight management therapy developed by Innovent, known as Mazdutide, has already showcased impressive results, with substantial weight loss and improvements in various health markers including blood pressure and cholesterol levels. This therapy has garnered international attention, being recognized as one of the “Top 10 Most Anticipated Medicines” of the upcoming year.
Future Directions of the Partnership
As Fangzhou and Innovent move forward, they are committed to deepening their collaboration. The goal is to broaden access to AI-driven health management while introducing innovative therapies that improve the quality and efficiency of chronic disease care across China. This partnership signifies a forward-thinking approach to healthcare that embraces technology and innovation.
About Innovent Biologics
Since its establishment in 2011, Innovent Biologics has been at the forefront of developing and commercializing innovative therapies targeting various health issues, including oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is recognized as China’s leading online chronic disease management platform, serving over 52.8 million registered users and 229,000 physicians as of mid-2025. The Company excels in providing tailored medical care and precision medicine solutions.
Frequently Asked Questions
What is the purpose of the partnership between Fangzhou and Innovent?
The partnership aims to integrate digital health services with innovative therapies for metabolic diseases and enhance weight management solutions.
What products are involved in Fangzhou's AI-driven ecosystem?
Fangzhou's ecosystem includes the AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search tools.
How does Mazdutide contribute to the partnership?
Mazdutide is a next-generation weight management therapy that has shown significant weight reduction and health benefits, making it a vital product in the partnership.
What market potential does the weight management sector in China hold?
Experts project that the weight management drug market in China could reach up to US$14.9 billion by 2030.
Who can benefit from Fangzhou’s digital health solutions?
Patients seeking personalized care for diabetes and obesity will benefit from the digital health tools and therapies provided through this partnership.
